Genetics and molecular biology of tuberous sclerosis complex

Valerio Napolioni, Paolo Curatolo, Valerio Napolioni, Paolo Curatolo

Abstract

Tuberous Sclerosis Complex is a multisystem disorder exhibiting a wide range of manifestations characterized by tumour-like lesions called hamartomas in the brain, skin, eyes, heart, lungs and kidneys. Tuberous Sclerosis Complex is genetically determined with an autosomal dominant inheritance and is caused by inactivating mutations in either the TSC1 or TSC2 genes. TSC1/2 genes play a fundamental role in the regulation of phosphoinositide 3-kinase (PI3K) signalling pathway, inhibiting the mammalian target of rapamycin (mTOR) through activation of the GTPase activity of Rheb. Mutations in TSC1/2 genes impair the inhibitory function of the hamartin/tuberin complex, leading to phosphorylation of the downstream effectors of mTOR, p70 S6 kinase (S6K), ribosomal protein S6 and the elongation factor binding protein 4E-BP1, resulting in uncontrolled cell growth and tumourigenesis.Despite recent promising genetic, diagnostic, and therapeutic advances in Tuberous Sclerosis Complex, continuing research in all aspects of this complex disease will be pivotal to decrease its associated morbidity and mortality. In this review we will discuss and analyse all the important findings in the molecular pathogenesis of Tuberous Sclerosis Complex, focusing on genetics and the molecular mechanisms that define this multisystemic disorder.

Keywords: Tuberous sclerosis; genetics; germ-line mosaicism; hamartin; multifactorial disease; mutations; rapamycin.; tuberin.

Figures

Fig. (1). Biochemical structure of hamartin and…
Fig. (1). Biochemical structure of hamartin and tuberin.
In this figure are rappresented the regulatory phosphorylation sites and respective kinases responsible for their phosphorylation.
Fig. (2)
Fig. (2)
Mutation spectra of TSC1 and TSC2.
Fig. (3). Tuberous sclerosis complex signalling.
Fig. (3). Tuberous sclerosis complex signalling.
Figure showing signalling pathways involved in the regulation of TSC complex controlling mammalian target of rapamycin (mTOR) activity. PI3K=phosphatidylinositol 3-kinase. PIP2=phosphatidyl-inositol (4,5) biphosphate. PIP3= phosphatidyl-inositol (3,4,5) triphosphate. PDK1= phosphoinositide-dependent protein kinase 1. PTEN= Phosphatase and tensin homolog. AKT=Protein kinase B. REDD-1=DNA-damage inducible transcript 4 protein. RSK-1=ribosomal protein S6 kinase alpha-1. LKB1=Serine/threonine-protein kinase 11. ERK=extracellular signal-related kinase. Rheb=Ras homologue enriched in brain. S6K1=ribosomal protein S6 kinase beta-1. 4E-BP1=eukaryotic translation initiation factor 4E-binding protein 1. eEF-2K=elongation factor 2 kinase. CDK1= Cyclin dependent Kinase 1.

References

    1. Curatolo P. London: Mac Keith Press; 2003. Tuberous Sclerosis Complex: From Basic Science to Clinical Phenotypes.
    1. Narayanan V. Tuberous sclerosis complex: Genetics to pathogenesis. Pediatr. Neurol. 2003;29:404–9.
    1. Gomez MR, Sampson JR, Whittemore VH. Tuberous Sclerosis Complex. Oxford: Oxford University Press; 1999.
    1. Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur. J. Pediatr. Neurol. 2002;6:15–23.
    1. Joinson C, O’Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol. Med. 2003;33:335–44.
    1. Curatolo P, Seri S, Verdecchia M, Bombardieri R. Infantile spasms in tuberous sclerosis complex. Brain Dev. 2001;23:502–7.
    1. Fukushima K, Inoue Y, Fujiwara T, Yagi K. Long-term follow-up study of West syndrome associated with tuberous sclerosis. Brain Dev. 2001;23:698–704.
    1. Gillberg IC, Gillberg C, Ahlsen G. Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study. Dev. Med. Child. Neurol. 1994;36:50–6.
    1. Shepherd CW, Houser OW, Gomez MR. MR findings in tuberous sclerosis complex and correlation with seizure development and mental impairment. Am. J. Neuroradiol. 1995;16:149–55.
    1. Bolton PF, Park RJ, Higgins JN, Griffiths PD, Pickles A. Neuroepileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain. 2002;125:1247–55.
    1. O’Callaghan FJ, Noakes MJ, Martyns CN, Osborne JP. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 2004;94:853–7.
    1. Casper KA, Donnelly LF, Chen B, Bissler JJ. Tuberous sclerosis complex: renal imaging findings. Radiology. 2002;225:451–6.
    1. Watson GH. Cardiac rhabdomyomas in tuberous sclerosis. Ann. NY Acad. Sci. 1991;615:50–7.
    1. Chorianopoulos D, Stratakos G. Lymphangioleiomyomatosis and Tuberous Sclerosis Complex. Lung. 2008
    1. Rowley SA, O’Callaghan FJ, Osborne JP. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br. J. Ophthalmol. 2001;85:420–3.
    1. Zimmer-Galler IE, Robertson DM. Long-term observation of retinal lesions in tuberous sclerosis. Am. J. Ophthalmol. 1995;119:318–24.
    1. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum. Genet. 2000;107:97–114.
    1. Sampson JR, Scahill SJ, Stephenson JB, Mann L, Connor JM. Genetic aspects of tuberous sclerosis in the west of Scotland. J. Med. Genet. 1989;26:28–31.
    1. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 2001;68:64–80.
    1. Jones AC, Shyamsundar MM, Thomas MW, Maynard J, Idziaszczyk S, Tomkins S, Sampson JR, Cheadle JP. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am. J. Hum. Genet. 1999;64:1305–15.
    1. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur. J. Hum. Genet. 2005;13:731–41.
    1. Au KS, Hebert AA, Roach ES, Northrup H. Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am. J. Hum. Genet. 1999;65:1790–5.
    1. Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat. Genet. 1994;6:193–6.
    1. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am. J. Hum. Genet. 1996;59:400–6.
    1. Niida Y, Stemmer-Rachamimov AO, Logrip M, Tapon D, Perez R, Kwiatkowski DJ, Sims K, MacCollin M, Louis DN, Ramesh V. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am. J. Hum. Genet. 2001;69:493–503.
    1. Han S, Santos TM, Puga A, Roy J, Thiele EA, McCollin M, Stemmer-Rachamimov A, Ramesh V. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer. Res. 2004;64:812–6.
    1. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Hal-ley D, Young J, Burley M, Jeremiah S, Woodward K, Nah-mias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP, Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali JB, Ward S, Green AJ, Yates JR, Kwiatkowska J, Henske EP, Short MP, Haines JH, Jozwiak S, Kwiatkowski DJ. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805–8.
    1. Ali M, Girimaji SC, Kumar A. Identification of a core promoter and a novel isoform of the human TSC1 gene transcript and structural comparison with mouse homolog. Gene. 2003;320:145–154.
    1. Sampson JR. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Biochem. Soc. Trans. 2003;31:592–6.
    1. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305–15.
    1. Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, Hall A. The TSC1 tumor suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat. Cell. Biol. 2000;2:281–7.
    1. Goncharova E, Goncharov D, Noonan D, Krymskaya VP. TSC2 modulates actin cytoskelton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J. Cell. Biol. 2004;167:1171–82.
    1. Haddad LA, Smith N, Bowser M, Niida Y, Murthy V, Gon-zalez-Agosti C, Ramesh V. The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskelton. J. Biol. Chem. 2002;277:44180–6.
    1. Maheshwar MM, Cheadle JP, Jones AC, Myring J, Fryer AE, Harris PC, Sampson JR. The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum. Mol. Genet. 1997;6:1991–6.
    1. York B, Lou D, Panettieri RA Jr, Krymskaya VP, Vanaman TC, Noonan DJ. Cross-talk between tuberin, calmodulin, and estrogen signalling pathways. FASEB J. 2005;19:1202–4.
    1. Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, Nellist M, Gamble V, Harris PC, Sampson JR. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease—a contiguous gene syndrome. Nat. Genet. 1994;8:328–32.
    1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N. Engl. J. Med. 2006;355:1345–56.
    1. Chong-Kopera H, Inoki K, Li Y, Zhu T, Garcia-Gonzalo FR, Luis Rosa J, Guan KL. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem. 2006;281:8313–6.
    1. Lu Z, Hu X, Li Y, Zheng L, Zhou Y, Jiang H, Ning T, Basang Z, Zhang C, Ke Y. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J. Biol. Chem. 2004;279:35664–70.
    1. Gan B, Melkoumian ZK, Wu X, Guan KL, Guan JL. Identification of FIP200 interaction with the TSC1-TSC2 complex and its role in regulation of cell size control. J. Cell. Biol. 2005;170:379–89.
    1. Nakashima A, Yoshino K, Miyamoto T, Eguchi S, Oshiro N, Kikkawa U, Yonezawa K. Identification of TBC7 having TBC domain as a novel binding protein to TSC1-TSC2 complex. Biochem. Biophys. Res. Commun. 2007;361:218–23.
    1. Nellist M, Burgers PC, van den Ouweland AM, Halley DJ, Luider TM. Phosphorylation and binding partner analysis of the TSC1-TSC2 complex. Biochem. Biophys. Res. Commun. 2005;333:818–26.
    1. Astrinidis A, Senapedis W, Henske EP. Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner. Hum. Mol. Genet. 2006;15:287–97.
    1. Rosner M, Hanneder M, Siegel N, Valli A, Hengstschläger M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat. Res. 2008;658:234–46.
    1. Jones AC, Daniells CE, Snell RG, Tachataki M, Idziaszczyk SA, Krawczak M, Sampson JR, Cheadle JP. Molecular genetic and phenotypic analysis reveals difference between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum. Mol. Genet. 1997;6:2155–61.
    1. Niida Y, Lawrence-Smith N, Banwell A, Hammer E, Lewis J, Beauchamp RL, Sims K, Ramesh V, Ozelius L. Analysis of both TSC1 and TSC2 for germline mutations in 126 urelated patients with tuberous sclerosis. Hum. Mutat. 1999;14:412–22.
    1. van Slegtenhorst M, Verhoef S, Tempelaars A, Bakker L, Wang Q, Wessels M, Bakker R, Nellist M, Lindhout D, Hal-ley D, van den Ouweland A. Mutational spectrum of TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation. J. Med. Genet. 1999;36:285–9.
    1. .
    1. Mayer K, Ballhausen W, Leistner W, Rott H. Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences. Biochim. Biophys. Acta. 2000;1502:495–507.
    1. Nellist M, Verhaaf B, Goedbloed MA, Reuser AJ, van den Ouweland AM, Halley DJ. TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum. Mol. Genet. 2001;10:2889–98.
    1. Nellist M, Sancak O, Goedbloed MA, Rohe C, van Netten D, Mayer K, Tucker-Williams A, van den Ouweland AM, Halley DJ. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex. Eur. J. Hum. Genet. 2005;13:59–68.
    1. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA. 2002;99:13571–6.
    1. Tee AR, Anjum R, Blenis J. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase (PI3K)/Akt-dependent and -independent phosphorylation of tuberin. J. Biol. Chem. 2003;278:37288–96.
    1. Nellist M, Sancak O, Goedbloed M, Adriaans A, Wessels M, Maat-Kievit A, Baars M, Dommering C, van den Ouweland A, Halley D. Functional characterisation of the TSC1-TSC2 complex to assess multiple TSC2 variants identified in single families affected by tuberous sclerosis complex. BMC Med. Genet. 2008;9:10.
    1. Roberts PS, Ramesh V, Dabora S, Kwiatkowski DJ. A 34 bp deletion within TSC2 is a rare polymorphism, not a pathogenic mutation. Ann. Hum. Genet. 2003;67:495–503.
    1. Sampson JR, Maheshwar MM, Aspinwall R, Thompson P, Cheadle JP, Ravine D, Roy S, Haan E, Bernstein J, Harris PC. Renal cystic disease in tuberous sclerosis: Role of the polycystic kidney disease 1 gene. Am. J. Hum. Genet. 1997;61:843–51.
    1. Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, Everitt J, Xu H, Kiguchi K, Landes G, Harris P, Walzer C. Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol. Cell. 2001;7:823–32.
    1. Ariyurek Y, Lantinga-van Leeuwen I, Spruit L, Ravine D, Breuning MH, Peters DJ. Large Deletions in the Polycystic Kidney Disease 1 (PKD1) Gene. Hum. Mutat. 2004;23:99.
    1. The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell. 1994;77:881–94.
    1. Thomas R, Mc Connell R, Whittacker J, Kirkpatrick P, Bradley J, Sandford R. Identification of mutations in the repeated part of the autosomal dominant polycystic kidney disease type 1 gene, PKD1, by long-range PCR. Am. J. Hum. Genet. 1999;65:39–49.
    1. Lee JK, Sayers TJ, Brooks AD, Back TC, Young HA, Komschlies KL, Wipsgginton JM, Wiltrout RH. IFN-g-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J. Immunol. 2000;164:231–9.
    1. Becker C, Pohla H, Frankenberger B, Schüler T, Assenmacher M, Schendel DJ, Blankenstein T. Adoptive tumor therapy with T lymphocytes enriched through an IFN-g capture assay. Nat. Med. 2001;7:1159–62.
    1. Dabora SL, Roberts P, Nieto A, Perez R, Jozwiak S, Franz D, Bissler J, Thiele EA, Sims K, Kwiatkowski DJ. Association between a high-expressing interferon-γ allele and a lower frequency of kidney angiomyolipomas in TSC2 Patients. Am. J. Hum. Genet. 2002;71:750–8.
    1. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-γ correlates with CA repeat polymorphism in the human IFN-γ gene. Eur. J. Immunogenet. 1999;26:1–3.
    1. Habib SL, Danial E, Nath S, Schneider J, Jenkinson CP, Duggirala R, Abboud HE, Thameem F. Genetic polymorphisms in OGG1 and their association with angiomyolipoma, a benign kidney tumor in patients with tuberous sclerosis. Cancer. Biol. Ther. 2007;8:7.
    1. Fahsold R, Rott HD, Lorenz P. A third gene locus for tuberous sclerosis is closely linked to the phenylalanine hydroxylase gene locus. Hum. Genet. 1991;88:85–90.
    1. Hall JG. Somatic mosaicism: observations related to clinical genetics. Am. J. Hum. Genet. 1988;43:355–63.
    1. van der Meulen MA, van der Meulen MJ, te Meerman GT. Recurrence risk for germinalmosaics revisited. J. Med. Genet. 1995;32:102–4.
    1. Northrup H, Wheless JW, Bertin TK, Lewis RA. Variability of expression in tuberous sclerosis. J. Med. Genet. 1993;30:41–3.
    1. Ruggieri M, Carbonare C, Magro G, Magone N, Grasso S, Tine A, Pavone L, Gomez MR. Tuberous sclerosis complex: neonatal deaths in three of four children of consanguineous, non-expressing parents. J. Med. Genet. 1997;34:256–260.
    1. Yates JRW, van Bakel I, Sepp T, Payne SJ, Webb DW, Nevin NC, Green AJ. Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis. Hum. Mol. Genet. 1997;6:2265–9.
    1. Rose VM, Au KS, Pollom G, Roach ES, Prashner HR, Northrup H. Germ-line mosaicism in tuberous sclerosis: how common? Am. J. Hum. Genet. 1999;64:986–92.
    1. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 2005;14:251–8.
    1. Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS. Aberrant b-Catenin Signaling in Tuberous Sclerosis. Am. J. Pathol. 2005;167:107–16.
    1. Astrinidis A, Senapedis W, Coleman TR, Henske EP. Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J. Biol. Chem. 2003;278:51372–9.
    1. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121:179–93.
    1. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA. 2004;101:13489–94.
    1. Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl. Acad. Sci. USA. 2005;102:667–72.
    1. Li Y, Inoki K, Vacratsis P, Guan KL. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J. Biol. Chem. 2003;278:13663–71.
    1. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol. Cell. 2002;10:151–62.
    1. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–90.
    1. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL. TSC2 Integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126:955–68.
    1. Yaffe MB, Cantley LC. Signal transduction. Grabbing phosphoproteins. Nature. 1999;402:30–1.
    1. Nellist M, Goedbloed MA, Halley DJ. Regulation of tuberous sclerosis complex (TSC) function by 14-3-3 proteins. Biochem. Soc. Trans. 2003;31:587–91.
    1. Shumway SD, Li Y, Xiong Y. 14-3-3 binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin. J. Biol. Chem. 2003;278:2089–92.
    1. Yasui S, Tsuzaki K, Ninomiya H, Floricel F, Asano Y, Maki H, Takamura A, Nanba E, Higaki K, Ohno K. The TSC1 gene product hamartin interacts with NADE. Mol. Cell. Neurosci. 2007;35:100–8.
    1. Mukai J, Hachiya T, Shoji-Hoshino S, Kimura MT, Nadano D, Suvanto P, Hanaoka T, Li Y, Irie S, Greene LA, Sato TA. NADE, a p75NTR-associated cell death executor, is involved in signal transduction mediated by the common neurotrophin receptor p75NTR. J. Biol. Chem. 2000;275:17566–70.
    1. Mukai J, Shiji S, Kimura MT, Okubo S, Sano H, Suvanto P, Li Y, Irie S, Sato TA. Structure-function analysis of NADE. J. Biol. Chem. 2002;227:13973–82.
    1. Wu EHT, Wu KHH, Wong YH. Tuberin: a stimulus-regulated tumor suppressor protein controlled by a diverse array of receptor tyrosine kinases and G protein-coupled receptors. Neurosignals. 2006;15:217–27.
    1. Cao Y, Kamioka Y, Yokoi N, Kobayashi T, Hino O, Ono-dera M, Mochizuki N, Nakae J. Interaction of FOXO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway. J. Biol. Chem. 2006;281:40242–51.
    1. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 2005;37:19–24.
    1. Tee AR, Blenis J. mTOR, translational control and human disease. Semin. Cell. Dev. Biol. 2005;16:29–37.
    1. Rosner M, Freilinger A, Hengstschläger M. Akt regulates nuclear/cytoplasmic localization of tuberin. Oncogene. 2007;26:521–31.
    1. Rosner M, Freilinger A, Hengstschläger M. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27. Mutat. Res. 2006;613:10–6.
    1. Carrano AC, Etan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell. Biol. 1999;1:193–9.
    1. Sutterlüty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Müller U, Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat. Cell. Biol. 1999;1:207–14.
    1. Rosner M, Hengstschläger M. Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J. Biol. Chem. 2004;279:48707–15.
    1. Ozcan U, Ozcan L, Yilmaz E, Düvel K, Sahin M, Manning BD, Hotamisligil GS. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell. 2008;29:541–51.
    1. Habib SL, Simone S, Barnes JJ, Abboud HE. Tuberin haploinsufficiency is associated with the loss of OGG1 in rat kidney tumors. Mol. Cancer. 2008;7:10.
    1. Kobayashi T, Mitani H, Takahashi R, Hirabayashi M, Ueda M, Tamura H, Hino O. Transgenic rescue from embryonic lethality and renal carcinogenesis in the Eker rat model by introduction of a wild-type Tsc2 gene. Proc. Natl. Acad. Sci. USA. 1997;94:3990–3.
    1. Rennebeck G, Kleymenova EV, Anderson R, Yeung RS, Artzt K, Walker CL. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. Proc. Natl. Acad. Sci. USA. 1998;95:15629–34.
    1. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, Onda H. A mouse model of TSC1 reveals sexdependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 2002;11:525–34.
    1. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat. Genet. 1995;9:70–4.
    1. Yeung RS, Katsetos CD, Klein-Szanto A. Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis. Am. J. Pathol. 1997;151:1477–86.
    1. Kobayashi T, Urakami S, Hirayama Y, Yamamoto T, Nishizawa M, Takahara T, Kubo Y, Hino O. Intragenic Tsc2 somatic mutations as Knudson's second hit in spontaneous and chemically induced renal carcinomas in the Eker rat model. Jpn. J. Cancer Res. 1997;88:254–61.
    1. Neufeld TP, de la Cruz AF, Johnston LA, Edgar BA. Coordination of growth and cell division in the Drosophila wing. Cell. 1998;93:1183–93.
    1. Leevers SJ, Weinkove D, MacDougall LK, Hafen E, Water-field MD. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 1996;15:6584–94.
    1. Böhni R, Riesgo-Escovar J, Oldham S, Brogiolo W, Stocker H, Andruss BF, Beckingham K, Hafen E. Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4. Cell. 1999;97:865–75.
    1. Verdu J, Buratovich MA, Wilder EL, Birnbaum MJ. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat. Cell. Biol. 1999;1:500–6.
    1. Gao X, Neufeld TP, Pan D. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. Dev. Biol. 2000;221:404–18.
    1. Cho KS, Lee JH, Kim S, Kim D, Koh H, Lee J, Kim C, Kim J, Chung J. Drosophila phosphoinositide-dependent kinase-1 regulates apoptosis and growth via the phosphoinositide 3-kinase-dependent signaling pathway. Proc. Natl. Acad. Sci. USA. 2001;98:6144–9.
    1. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, Thomas G. Drosophila S6 kinase: a regulator of cell size. Science. 1999;285:2126–9.
    1. Ito N, Rubin GM. Gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell. 1999;96:529–39.
    1. Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes. Dev. 2001;15:1383–92.
    1. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell. 2001;105:345–55.
    1. Matsumoto S, Bandyopadhyay A, Kwiatkowski DJ, Maitra U, Matsumoto T. Role of the Tsc1-Tsc2 complex in signalling and transport across the cell membrane in the fission yeast Schizosaccharomyces pombe. Genetics. 2002;161:1053–63.
    1. Jozwiak J, Jozwiak S, Oldak M. Molecular activity of sirolimus and its possible applications in tuberous sclerosis treatment. Med. Res. Rev. 2006;26:160–80.
    1. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Bu-rakoff SJ, Crabtree G, Schreiber SL. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA. 1990;87:9231–5.
    1. Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 2003;63:8451–60.
    1. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003;4:147–58.
    1. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethura-man G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 2006;59:490–8.
    1. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 2008;358:140–51.
    1. Rauktys A, Lee N, Lee L, Dabora SL. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol. 2008;8:1.
    1. Schwartz RA, Fernandez G, Kotulska K, Jozwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics and management. J. Am. Acad. Dermatol. 2007;57:189–202.
    1. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 2008;63:444–53.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit